March 16 (Reuters) - Incyte Corp, Eli Lilly :
* LILLY RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR BARICITINIB FOR THE TREATMENT OF ALOPECIA AREATA
* ELI LILLY AND COMPANY- FDA HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION TO BARICITINIB FOR TREATMENT OF ALOPECIA AREATA Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.